BIOGEN 105MS401 (POP)
Plegridy (PEGINTERFERON β-1A) REAL WORLD EFFECTIVENESS AND SAFETY OBSERVATIONAL PROGRAM
ACORDA (DALF-PS-1016)
A DOUBLE BLIND, PLACEBO CONTROLLED, PARALEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE
STRENGHTS OF DALFAMPRIDINE EXTENDED RELEASE TABLETS FOR TREATMENT OF STABLE WALKING DEFICITS IN POSTISCHEMIC STROKE (MILESTONE)
BIOGEN 109MS404 (RESPOND)
A MULTICENTER,OPEN-LABEL,12-MONTH OBSERVATIONAL STUDY EVALUATING THE CLINICAL EFFECTIVENESS AND IMPACT ON
PATIENT-REPORTED OUTCOMES OF ORAL TECFIDERA (DIMETHYL FUMARATE) DELAYED RELEASE CAPSULES IN PATIENTS WITH
RELAPSING FORMS OF MULTIPLE SCLEROSIS AFTER SUBOPTIMAL RESPONSE TO GLATIRAMER ACETATE
BIOGEN (ESTEEM)
A MULTICENTER, GLOBAL, OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG
UTILIZATION OF TECFIDERA (DIMETHYL FUMARATE) WHEN USED IN ROUTINE MEDICAL PRACTICE IN THE TREATMENT OF
MULTIPLE SCLEROSIS
LABRYS BIOLOGICS
A MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED PARALLEL-GROUP,STUDY COMPARING THE EFFICACY AND SAFETY OF
TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF HIGH FREQUENCY EPISODIC
MIGRAINE
LABRYS BIOLOGICS
A MULTICENTER, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED PARALLEL-GROUP,MULTI-DOSE STUDY
COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE
TREATMENT OF CHRONIC MIGRAINE
AVANIR PHARMACEUTICALS,INC
A STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFECTIVENESSOF NEUDEXTA (DEXTROMETHORPHAN 20MG/QUINIDINE
10MG) IN THE TREATMENT OF PSEUDOBULBAR AFFECT (PBA)
MARINUS (POS)
A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF
GANAXOLONE AS ADJUNCTIVE THERAPY FOR ADULTS WITH THE DRUG-RESISTANT PARTIAL-ONSET SEIZURES FOLLOWED BY
LONG-TERM OPEN-LABEL TREATMENT
MERCK 8931-019 (PRODROMAL AD)
A PHASE II/III RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND CLINICAL TRIAL TO STUDY THE
EFFICACY AND SAFETY OF MK 8931 IN SUBJECT WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE
(PRODROMAL AD)
SANOFI LPS13567 (RELAPSING MULTIPLE SCLEROSIS)
A PROSPECTIVE, SINGLE ARM, CLINICAL-SETTING STUDY TO DESCRIBE EFFICACY, TOLERABILITY AND CONVENIENCE OF
TERIFLUNOMIDE TREATMENT USING PATIENT REPORTED OUTCOMES (PROs) IN RELAPSING MULTIPLE SCLEROSIS (RMS)
PATIENTS
SHIONOGI 1326V9235 (OIC)
A RANDOMIZED DOUBLE-BLIND,PLACEBO-CONTROLLED,PARALLEL-GROUP,MULTICENTER,PHASE 3 STUDY TO EVALUATE THE
LONG-TERM SAFETY OF NALDEMEDINE FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN SUBJECTS WITH NONMALIGNANT CHRONIC PAIN RECEIVING OPIOID THERAPY
CUBIST 5945-SOIC-12-05 (OIC)
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE LONG- TERM
SAFETY AND TOLERABILITY OF CB-5945 FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN ADULTS TAKING OPIOID
THERAPY FOR CHRONIC NON-CANCER PAIN
CUBIST 5945-SOIC-12-02 (OIC)
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND
SAFETY OF CB-5945 FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN ADULTS TAKING OPIOID THERAPY FOR
CHRONIC NON-CANCER PAIN
UCB N01358 (BRIVARACETAM PARTIAL ONSET SEIZURES)
A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY
AND SAFETY OF BRIVARACETAM IN SUBJECTS (> 16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES
UCB N01379 (BRIVARACETAM PARTIAL ONSET SEIZURES)
AN OPEN-LABEL,MULTICENTER,FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM
USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY
PFIZER A0081105 (EPILEPSY PRIMARY GENERALIZED TONIC CLONIC SEIZURES)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL OF PREGABALIN AS
ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC CLONIC SEIZURES
ALLERGAN GMA-BTX-CM-10-001 (COMPEL / Botox)
AN OPEN LABEL, MULTICENTER STUDY OF THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF BOTOX
(ONABOTULINUMTOXINA) FOR THE PROPHYLAXIS OF HEADACHES IN ADULT PATIENTS WITH CHRONIC MIGRAINE (THE COMPEL
STUDY)
ASTRAZENECA 12AST11894/A-12292 (OIC Burden of Illness)
LONGITUDINAL STUDY OF PATIENTS WITH OPIOID-INDUCED CONSTIPATION
MERCK 8931-017 (Alzheimer’s Disease)
A RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND EFFICACY AND SAFETY TRIAL OF MK-8931 IN
SUBJECTS MILD TO MODERATE ALZHEIMER’S DISEASE
NOVARTIS CFTY720DUS09 (PREFERMS)
12-MONTH, PROSPECTIVE, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE PATIENT RETENTION
OF FINGOLIMOD VS. APPROVED FIRST-LINE DISEASE MODIFYING THERAPIES IN ADULTS WHO ARE IN EARLY STAGES OF
TREATMNET FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (PREFERMS)
UCB SP0980 (VIMPAT)
A PROSPECTIVE,MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATORY STUDY TO EVALUATE THE TOLERABLITY AND
EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL
BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES
PFIZER A0081106 (Pediatric Epilepsy)
A 12-MONTH OPEN-LABEL STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF PREGABALIN AS ADJUNCTIVE
THERAPY IN PEDIATRIC SUBJECTS 1 MONT TO 16 YEARS OF AGE WITH PARTIAL ONSET SEIZURES AND PEDIATRIC
AND ADULT SUBJECTS 5 TO 65 YEARS OF AGE WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
SHIONOGI 1107V9221 (OIC)
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY OF S-297995 FOR THE TREATMENT OF
OPIOID-INDUCED CONSTIPATION (OIC) IN SUBJECTS WITH NON-MALIGNANT PAIN RECEIVING OPIOID THERAPY
SEPRACOR 093-050 (Epilepsy)
LONG-TERM ESLICARBAZEPINE ACETATE EXTENSION STUDY
BIOGEN 101JC402 (JCV)
JCV ANTIBODY PROGRAM IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS RECEIVING OR CONSIDERING
TREATMENT WITH TYSABRI/STRATIFY -2
TEVA (COPAXONE)
AN OPEN-LABEL, MULTICENTER STUDY EVALUATING PATIENT INJECTION SATISFACTION WITH TWO FORMULATIONS OF
COPAXONE FOR SUBCUTANEOUS INJECTION UTILIZING AUTOJECT 2 DEVICES
NOVARTIS CFTY720DUS01 (EPOC)
A 6 MONTH, RANDOMIZED, ACTIVE COMPARATOR, OPEN-LABEL, MULTI-CENTER, STUDY TO EVALUATE PATIENT OUTCOMES,
SAFETY AND TOLERABILITY OF FINGOLIMOD/DAY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO ARE
CANDIDATES FOR MS THERAPY CHANGE FROM PREVIOUS DISEASE MODIFYING THERAPY (EPOC)
CHELSEA THERAPEUTICS NOH306 (PARKINSON’S)
A MULTI CENTER,DOUBLE-BLIND,RANDOMIZED,PARALLEL-GROUP,PLACEBO-CONTROLLED STUDY TO ASSESS THE CLINICAL
EFFECT OF DROXIDOPA IN THE TREATMENT OF SYMPTOMATIC NEUROGENIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH
PARKINSON’S DISEASE
ASTRAZENECA D3820C00008 (OIC)
AN OPEN-LABEL 52-WEEK STUDY TO ASSESS THE LONG-TERM SAFETY OF NKTR-118 IN OPIOID-INDUCED CONSTIPATION (OIC) IN
PATIENTS WITH NON-CANCER-RELATED PAIN
SEPRACOR 093-046 (Epilepsy)
11/2010-AUG 2012
DOUBLE-BLIND, RANDOMIZED, HISTORICAL CONTROL STUDY OF THE SAFETY AND EFFICACY OF ESLICARBAZEPINE ACETATE
MONOTHERAPY IN SUBJECTS WITH PARTIAL EPILEPSY NOT WELL CONTROLLED BY CURRENT ANTIEPILEPTIC DRUGS
SP0954 (VIMPAT) EPILEPSY PARTIAL ONSET SEIZURES
07/2010-11/2012
AN OPEN-LABEL, MULTICENTER, MULTINATIONAL STUDY OF LACOSIMIDE AS FIRST ADD-ON ANTIEPILEPTIC DRUG (AED)
TREATMENT IN SUBJECTS WITH PARTIAL-ONSET SEIZURES